北京第一生物科技开发有限公司

Beijing First Biological Technology Development Co., Ltd. is a Chinese biopharmaceutical company established in 1994 and headquartered in the Beijing Economic-Technological Development Area. The company specializes in the research, development, and production of biological medicines, with a particular focus on liver-related therapies and immune modulators. Its flagship product, Shengli (Liver Extract and Vitamin B12 Injection), is a widely recognized biological response modifier used in the treatment of chronic hepatitis, liver cirrhosis, and radiation-induced leukopenia. Beijing First Biological operates a modern, GMP-certified manufacturing facility and maintains a significant presence in the Chinese domestic market. The company is dedicated to advancing biological extraction technologies to provide effective treatments for chronic and debilitating diseases.